Literature DB >> 25740073

The role of the mediators of inflammation in cancer development.

José Veríssimo Fernandes1, Ricardo Ney Oliveira Cobucci, Carlos André Nunes Jatobá, Thales Allyrio Araújo de Medeiros Fernandes, Judson Welber Veríssimo de Azevedo, Josélio Maria Galvão de Araújo.   

Abstract

Epigenetic disorders such as point mutations in cellular tumor suppressor genes, DNA methylation and post-translational modifications are needed to transformation of normal cells into cancer cells. These events result in alterations in critical pathways responsible for maintaining the normal cellular homeostasis, triggering to an inflammatory response which can lead the development of cancer. The inflammatory response is a universal defense mechanism activated in response to an injury tissue, of any nature, that involves both innate and adaptive immune responses, through the collective action of a variety of soluble mediators. Many inflammatory signaling pathways are activated in several types of cancer, linking chronic inflammation to tumorigenesis process. Thus, Inflammatory responses play decisive roles at different stages of tumor development, including initiation, promotion, growth, invasion, and metastasis, affecting also the immune surveillance. Immune cells that infiltrate tumors engage in an extensive and dynamic crosstalk with cancer cells, and some of the molecular events that mediate this dialog have been revealed. A range of inflammation mediators, including cytokines, chemokines, free radicals, prostaglandins, growth and transcription factors, microRNAs, and enzymes as, cyclooxygenase and matrix metalloproteinase, collectively acts to create a favorable microenvironment for the development of tumors. In this review are presented the main mediators of the inflammatory response and discussed the likely mechanisms through which, they interact with each other to create a condition favorable to development of cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740073     DOI: 10.1007/s12253-015-9913-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  63 in total

Review 1.  COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention.

Authors:  Mary-Clare Cathcart; Kenneth J O'Byrne; John V Reynolds; Jacintha O'Sullivan; Graham P Pidgeon
Journal:  Biochim Biophys Acta       Date:  2011-10-01

Review 2.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

Review 3.  Chemokines in cancer related inflammation.

Authors:  Paola Allavena; Giovanni Germano; Federica Marchesi; Alberto Mantovani
Journal:  Exp Cell Res       Date:  2010-12-04       Impact factor: 3.905

Review 4.  Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors:  Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal:  Cancer Treat Rev       Date:  2012-05-29       Impact factor: 12.111

Review 5.  The role of COX-2 in intestinal inflammation and colorectal cancer.

Authors:  D Wang; R N Dubois
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

6.  Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50.

Authors:  F Driessler; K Venstrom; R Sabat; K Asadullah; A J Schottelius
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

Review 7.  MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Carlo M Croce
Journal:  Immunol Rev       Date:  2013-05       Impact factor: 12.988

Review 8.  Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation.

Authors:  Tsutomu Chiba; Hiroyuki Marusawa; Toshikazu Ushijima
Journal:  Gastroenterology       Date:  2012-07-13       Impact factor: 22.682

9.  Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback.

Authors:  Michael J Pattison; Kirsty F Mackenzie; J Simon C Arthur
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

Review 10.  Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling.

Authors:  Qishan Chen; Min Jin; Feng Yang; Jianhua Zhu; Qingzhong Xiao; Li Zhang
Journal:  Mediators Inflamm       Date:  2013-06-12       Impact factor: 4.711

View more
  65 in total

1.  DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway.

Authors:  Fan Zhang; Bufu Tang; Zijiao Zhang; Di Xu; Guowu Ma
Journal:  Inflammation       Date:  2019-04       Impact factor: 4.092

2.  Associations between fruit and vegetable variety and low-grade inflammation in Portuguese adolescents from LabMed Physical Activity Study.

Authors:  Juliana Almeida-de-Souza; Rute Santos; Luis Lopes; Sandra Abreu; Carla Moreira; Patrícia Padrão; Jorge Mota; Pedro Moreira
Journal:  Eur J Nutr       Date:  2017-06-14       Impact factor: 5.614

3.  Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.

Authors:  Katherine A Scilla; Søren M Bentzen; Vincent K Lam; Pranshu Mohindra; Elizabeth M Nichols; Melissa A Vyfhuis; Neha Bhooshan; Steven J Feigenberg; Martin J Edelman; Josephine L Feliciano
Journal:  Oncologist       Date:  2017-05-22

Review 4.  Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy.

Authors:  Meng Lan; Wenping Lu; Tengteng Zou; Lihong Li; Fengjie Liu; Tiange Cai; Yu Cai
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

Review 5.  Exosomes and cancer: from molecular mechanisms to clinical applications.

Authors:  Ameneh Jafari; Amirhesam Babajani; Meghdad Abdollahpour-Alitappeh; Nayebali Ahmadi; Mostafa Rezaei-Tavirani
Journal:  Med Oncol       Date:  2021-03-20       Impact factor: 3.064

Review 6.  Macrophage Migration Inhibitory Factor (MIF): Biological Activities and Relation with Cancer.

Authors:  Camila Cristina Guimarães Nobre; Josélio Maria Galvão de Araújo; Thales Allyrio Araújo de Medeiros Fernandes; Ricardo Ney Oliveira Cobucci; Daniel Carlos Ferreira Lanza; Vânia Sousa Andrade; José Veríssimo Fernandes
Journal:  Pathol Oncol Res       Date:  2016-10-23       Impact factor: 3.201

7.  Estimated Glomerular Filtration Rate and the Risk of Cancer.

Authors:  Hong Xu; Kunihiro Matsushita; Guobin Su; Marco Trevisan; Johan Ärnlöv; Peter Barany; Bengt Lindholm; Carl-Gustaf Elinder; Mats Lambe; Juan-Jesus Carrero
Journal:  Clin J Am Soc Nephrol       Date:  2019-03-14       Impact factor: 8.237

Review 8.  Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics.

Authors:  Himadri Patel; Pritish Nilendu; Devashree Jahagirdar; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cancer Biol Ther       Date:  2017-12-08       Impact factor: 4.742

Review 9.  Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases.

Authors:  Gil Aizik; Etty Grad; Gershon Golomb
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

10.  BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF-кB signaling pathway.

Authors:  Ran Zhao; Yukun Liu; Heran Wang; Jing Yang; Weihong Niu; Songqing Fan; Wei Xiong; Jian Ma; Xiaoling Li; Joshua B Phillips; Ming Tan; Yuanzheng Qiu; Guiyuan Li; Ming Zhou
Journal:  Cell Mol Immunol       Date:  2016-07-04       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.